Insmed (INSM) Revenue Growth (3y) (2013 - 2026)
Insmed (INSM) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | 79.44% |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 54.05% |
| 10 | Insmed | 22.94 Bn | 21.71 Bn | 258.54 Mn | 67.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.41% |
| Dec 31, 2025 | 64.47% |
| Sep 30, 2025 | 28.09% |
| Jun 30, 2025 | 18.09% |
| Mar 31, 2025 | 20.46% |
| Dec 31, 2024 | 23.00% |
| Sep 30, 2024 | 25.95% |
| Jun 30, 2024 | 25.81% |
| Mar 31, 2024 | 23.36% |
| Dec 31, 2023 | 26.43% |
| Sep 30, 2023 | 21.91% |
| Jun 30, 2023 | 22.03% |
| Mar 31, 2023 | 20.95% |
| Dec 31, 2022 | 9.07% |
| Sep 30, 2022 | 20.32% |
| Jun 30, 2022 | 29.59% |
| Mar 31, 2022 | 34.35% |
| Dec 31, 2021 | 78.70% |
| Jun 30, 2013 | 83.41% |